Jane Street’s Elicio Therapeutics ELTX Stock Holding History

Jane Street’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$145K	Buy	+13,600	New	+$131K	﹤0.01%	10417

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jane Street's ELTX Position: Q2 2025 in Review

Jane Street sold out of Elicio Therapeutics (ELTX) in Q2 2025, closing a stake of 14,993 shares — an estimated $92.4K sold.

Jane Street first reported a position in ELTX in Q1 2025 and held it in 1 quarter. The position peaked at $92.4K in Q1 2025. 21 funds tracked by Wall St. Rank hold ELTX as of Q2 2025.

Jane Street reported no remaining Elicio Therapeutics position as of Q2 2025 after selling out during the quarter.
Jane Street sold 14,993 Elicio Therapeutics shares in Q2 2025, an estimated $92.4K.
Jane Street first reported a position in Elicio Therapeutics in Q1 2025 and held it in 1 quarter.
Jane Street's Elicio Therapeutics position peaked at $92.4K in Q1 2025.
21 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2025.

Based on Jane Street's 13F filing for Q2 2025, filed 14 Aug 2025.